Introduction {#sec1-0300060520904814}
============

Maternal thyroid hormones play a critical role in maintaining systemic homeostasis and have been shown to be associated with many health-related effects in mothers and their children.^[@bibr1-0300060520904814]^ Several studies have shown that thyroid dysfunction is associated with hypertensive disorders during pregnancy.^[@bibr2-0300060520904814][@bibr3-0300060520904814]--[@bibr4-0300060520904814]^ Hypertensive disorders of pregnancy include chronic hypertension, gestational hypertension (GH), preeclampsia, and eclampsia, with an estimated prevalence of 4% to 11% among pregnant women in China.^[@bibr5-0300060520904814],[@bibr6-0300060520904814]^ GH is a major cause of maternal and infant morbidity and mortality. Some observational studies have shown that mothers with hypothyroidism have an increased risk of GH.^[@bibr7-0300060520904814]^ However, other studies have shown less conclusive associations between milder forms of maternal thyroid dysfunction and GH.^[@bibr8-0300060520904814]^ Most of these studies were conducted among Western populations and had a limited sample size. Furthermore, numerous studies on this topic have also been published in the last decade. Since 2016, the two-child policy was fully implemented in China, and pregnancy at advanced maternal age has become more common. This has caused new challenges in pregnancy management and treatment of pregnancy complications.^[@bibr9-0300060520904814]^ The incidence of GH is significantly higher than that prior to implementation of the two-child policy, and this trend may be related to increased maternal age.^[@bibr10-0300060520904814]^ International scientific society guidelines also consider a maternal age of \>30 years to be a risk factor for hypothyroidism in pregnancy, and screening for thyroid function is recommended.^[@bibr11-0300060520904814],[@bibr12-0300060520904814]^ However, few studies have focused on the relationship between maternal thyroid function and GH. In this epidemiological study, we estimated the associations between thyroid function during early pregnancy and GH.

Material and methods {#sec2-0300060520904814}
====================

Ethics statement {#sec3-0300060520904814}
----------------

The protocol and design of this prospective cohort study were approved by the hospital ethics and scientific committees of the Jiangxi Maternal and Child Health Hospital, Nanchang, China. All participants provided written informed consent.

Study design and participants {#sec4-0300060520904814}
-----------------------------

From May 2015 to September 2017, participants were recruited at their prenatal visit at Jiangxi Maternal and Child Health Hospital. The inclusion criteria were a hospital visit at the 9th to 13th weeks of gestation, singleton pregnancy, and planning to give birth in the study hospital. Pregnant women with chronic hypertension, a history of thyroid disease, and no thyroid measurements were excluded. Data on individual participants were collected using questionnaires during the 9th to 13th weeks of gestation. The pre-pregnancy weight and height were self-reported. In total, 1226 pregnant women were included in the final analysis.

Thyroid hormone measurements {#sec5-0300060520904814}
----------------------------

Blood samples were collected at the outpatient clinic during the 9th to 13th weeks of gestation. Thyroid-related parameters, including the concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine, were measured using electrochemiluminescence immunoassays according to the manufacturer's protocols. The reference ranges for TSH and FT4 were calculated according to the 2.5th to 97.5th percentiles. Clinical thyroid dysfunction was defined as follows: hyperthyroidism (TSH of \<0.3 mIU/mL and FT4 of \>14.4 pmol/L), subclinical hyperthyroidism (TSH of \<0.3 mIU/mL and normal FT4), hypothyroidism (TSH of \>3 mIU/mL and FT4 of \<7.9 pmol/L), and subclinical hypothyroidism (TSH of \>3.0 mIU/mL and normal FT4).

Maternal GH {#sec6-0300060520904814}
-----------

The diagnoses of GH and preeclampsia were obtained from the electronic medical records linked to the participant inpatient and outpatient records. GH and preeclampsia were clinically diagnosed according to the American College of Obstetricians and Gynecologists guidelines of 2013.^[@bibr13-0300060520904814]^ Briefly, GH was defined as systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg before 20 weeks of gestation with normal blood pressure. The outcome of GH was reconfirmed before delivery; that is, the diagnosis was not based only on a single outpatient visit or single blood pressure measurement. Preeclampsia was diagnosed using the above-mentioned criteria plus the presence of proteinuria (urine protein level of ≥0.3 g/24 hours). In the present study, data on GH and preeclampsia were analyzed together.

Statistical analysis {#sec7-0300060520904814}
--------------------

Normally distributed variables are expressed as mean ± standard deviation and were compared using Student's t-test. The chi-square test or Fisher's exact test was used to compare proportions between the two groups. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations of thyroid dysfunction with GH and the associations of TSH and FT4 quintiles with GH were estimated using logistic regression models adjusted for maternal age, education, parity, current delivery mode, pre-pregnancy body mass index, gestational weight gain, and newborn sex. All reported p-values were two-sided, and p-values of \<0.05 were considered statistically significant. The statistical analysis was performed using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA).

Results {#sec8-0300060520904814}
=======

Of 1226 pregnant women, 81 (6.6%) developed GH. The characteristics of the pregnant women with and without GH are shown in [Table 1](#table1-0300060520904814){ref-type="table"}. Compared with women without GH, women with GH were more likely to have advanced maternal age and higher pre-pregnancy body mass index. There were no significant differences in maternal education, delivery modes, or newborn sex between the two groups.

###### 

Characteristics of pregnant women with and without GH (n = 1226).

![](10.1177_0300060520904814-table1)

  Characteristics                      Women without GH   Women with GH   *P* value
  ------------------------------------ ------------------ --------------- -----------
  Maternal age at birth, years         28.8 ± 4.7         30.1 ± 5.1      0.016
  Education                                                               
   High school or less                 165 (14.4)         19 (23.5)       0.088
   College                             444 (38.8)         28 (34.6)       
   Undergraduate or above              536 (46.8)         34 (42.0)       
  Gestational age at delivery, weeks   38.2 ± 2.1         35.6 ± 3.4      \<0.001
  Parity                                                                  
   0                                   686 (59.9)         39 (48.1)       0.037
   ≥1                                  459 (40.1)         42 (51.9)       
  Pre-pregnancy BMI, kg/m^2^                                              
   \<18.5                              237 (20.7)         13 (16.0)       0.021
   18.5--25.0                          783 (68.4)         51 (63.0)       
   \>25.0                              125 (10.9)         17 (21.0)       
  Gestational weight gain, kg          13.1 ± 4.7         12.9 ± 4.6      0.934
  Delivery modes                                                          
   Vaginal delivery                    946 (82.6)         60 (74.1)       0.053
   Cesarean delivery                   199 (17.4)         21 (25.9)       
  Newborn sex                                                             
   Male                                687 (60.0)         47 (58.0)       0.726
   Female                              458 (40.0)         34 (42.0)       
  TSH, mIU/mL                          1.12 ± 0.85        1.56 ± 1.33     0.014
  FT4, pmol/L                          15.20 ± 2.11       16.93 ± 3.08    0.705
  FT3, pmol/L                          6.94 ± 1.05        7.21 ± 2.14     0.355
  Thyroid dysfunction                                                     
   Hypothyroidism                      29 (2.5)           7 (8.6)         0.002
   Subclinical hypothyroidism          62 (5.4)           9 (11.1)        0.061
   Hyperthyroidism                     18 (1.6)           3 (3.7)         0.153
   Subclinical hyperthyroidism         27 (2.4)           4 (4.9)         0.201

Data are presented as n (%) for categorical variables and mean ± standard deviation for continuous variables.

BMI, body mass index; TSH, thyroid-stimulating hormone; FT4, free thyroxine; FT3, free triiodothyronine; GH, gestational hypertension.

Compared with women with euthyroidism, the logistic regression analysis showed that both pregnant women with hypothyroidism and those with subclinical hypothyroidism had a higher risk of GH (adjusted OR, 3.61; 95% CI, 1.52--8.57 and adjusted OR, 2.24; 95% CI, 1.06--4.72, respectively). No associations were found between hyperthyroidism or subclinical hyperthyroidism and GH ([Table 2](#table2-0300060520904814){ref-type="table"}). Further analysis of the risk of GH according to quintiles of the TSH level is presented in [Table 3](#table3-0300060520904814){ref-type="table"}. Women in the fifth quintile of TSH had a higher risk of GH (adjusted OR, 4.22; 95% CI, 1.78--9.05) than those in the third quintile. No significant associations between GH and FT4 were observed by analyzing FT4 defined by quintiles ([Table 4](#table4-0300060520904814){ref-type="table"}).

###### 

Thyroid dysfunction and risk of gestational hypertension.

![](10.1177_0300060520904814-table2)

  Thyroid dysfunction           n      n (%) with GH   OR (95% CI)         *P* value
  ----------------------------- ------ --------------- ------------------- -----------
  Hypothyroidism                36     7 (19.4)        3.61 (1.52--8.57)   0.004
  Subclinical hypothyroidism    71     9 (12.6)        2.24 (1.06--4.72)   0.033
  Hyperthyroidism               21     3 (14.2)        2.26 (0.76--8.63)   0.161
  Subclinical hyperthyroidism   31     4 (12.9)        1.87 (0.63--5.58)   0.258
  Euthyroidism (reference)      1067   58 (5.4)        Reference           

ORs were adjusted for maternal age, education, parity, delivery mode, pre-pregnancy body mass index, gestational weight gain, and newborn sex.

GH, gestational hypertension; OR, odds ratio; CI, confidence interval.

###### 

Risk of gestational hypertension by quintile categories of TSH.

![](10.1177_0300060520904814-table3)

  TSH by quintile   n     n (%) with GH   OR (95% CI)         *P* value
  ----------------- ----- --------------- ------------------- -----------
  Q1                242   11 (4.5)        1.26 (0.65--2.47)   0.574
  Q2                247   16 (6.4)        2.23 (0.87--4.68)   0.104
  Q3 (reference)    241   10 (4.1)        Reference           
  Q4                247   18 (7.3)        2.72 (0.91--5.74)   0.092
  Q5                249   26 (10.4)       4.22 (1.78--9.05)   0.001

ORs were adjusted for maternal age, education, parity, delivery mode, pre-pregnancy body mass index, gestational weight gain, and newborn sex.

TSH, thyroid-stimulating hormone; GH, gestational hypertension; OR, odds ratio; CI, confidence interval.

###### 

Risk of gestational hypertension by quintile categories of FT4.

![](10.1177_0300060520904814-table4)

  FT4 by quintile   n     n (%) with GH   OR (95% CI)         *P* value
  ----------------- ----- --------------- ------------------- -----------
  Q1                244   21 (8.6)        1.37 (0.61--2.62)   0.404
  Q2                246   18 (7.3)        1.26 (0.58--2.91)   0.551
  Q3 (reference)    246   14 (5.6)        Reference           
  Q4                244   15 (6.1)        1.18 (0.57--2.49)   0.652
  Q5                246   13 (5.3)        1.11 (0.52--2.33)   0.791

ORs were adjusted for maternal age, education, parity, delivery mode, pre-pregnancy body mass index, gestational weight gain, and newborn sex.

GH, gestational hypertension; OR, odds ratio; CI, confidence interval; FT4, free thyroxine.

Discussion {#sec9-0300060520904814}
==========

In this prospective cohort study, we evaluated the associations of maternal thyroid hormone parameters during early pregnancy with GH. We found that hypothyroidism, subclinical hypothyroidism, and high TSH levels were associated with an increased risk of GH, findings that agree with those of previous studies.^[@bibr14-0300060520904814]^ At present, universal thyroid screening during pregnancy remains controversial.^[@bibr15-0300060520904814]^ Our study adds an important piece of evidence showing that early diagnosis and treatment may result in improved pregnancy outcomes.

In this population-based study, our results strengthen the notion of the association between hypothyroidism and GH.^[@bibr16-0300060520904814]^ Thyroid hormones are essential for maintaining homeostasis as evidenced by the myriad effects of thyroid hormone deficiency. Hypothyroidism significantly interferes with the cardiovascular system, leading to changes in left ventricular function, decreased cardiac output, and increased systemic vascular resistance.^[@bibr17-0300060520904814]^ Although some observational studies have demonstrated associations between subclinical hypothyroidism and hypertensive disorders during pregnancy, limited sample sizes and conflicting results have been reported.^[@bibr18-0300060520904814],[@bibr19-0300060520904814]^ Wilson et al.^[@bibr20-0300060520904814]^ found that subclinical hypothyroidism was associated with an increased risk of GH. A meta-analysis showed that subclinical hypothyroidism was associated with several adverse pregnancy outcomes, including placental abruption, premature rupture of membranes, and neonatal death; however, it did not show an increased risk of GH.^[@bibr21-0300060520904814]^ Our study showed that various types of thyroid dysfunction have various effects on GH in pregnancy. Several studies have revealed that hyperthyroidism and high FT4 levels are risk factors for hypertensive disorders during pregnancy.^[@bibr7-0300060520904814],[@bibr22-0300060520904814]^ While our study included a relatively large sample size, few patients had hyperthyroidism, attributable to the lack of statistical power to produce this finding.

When the TSH and FT4 levels were analyzed using the entire range, we found a significant positive association between the highest TSH quintile (but not the highest FT4 quintile) and the risk of GH. Thyroid hormones act directly to increase peripheral resistance and endothelial dysfunction, causing GH.^[@bibr23-0300060520904814][@bibr24-0300060520904814]--[@bibr25-0300060520904814]^ Our study does not agree with the findings of the Generation R Study, a prospective cohort study showing that high FT4 but not TSH levels during early pregnancy were associated with a significantly increased risk of hypertensive disorders.^[@bibr22-0300060520904814]^ These differing results might be partially attributable to the study population consisting of pregnant women. In the Generation R Study, the incidence of overt hyperthyroidism was relatively high, while hypothyroidism was rare; this is in contrast to the results of our study. The lack of significant findings may also be due to the small sample size. A major limitation of our study is that the TSH and FT4 levels were only tested in early pregnancy. The current study was conducted in one specific region of China; therefore, generalizability to the entire population is limited. Only the diagnosis of GH was obtained from the electronic medical records; the systolic blood pressure and diastolic blood pressure were not extracted. We were unable to examine the associations of thyroid hormone parameters and the continuous variable of blood pressure.

Conclusions {#sec10-0300060520904814}
===========

Our results support those of previous studies showing that hypothyroidism, subclinical hypothyroidism, and a high TSH level during early pregnancy are risk factors for GH. Future research will clarify whether women at risk of GH benefit from thyroid medication during early pregnancy.
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